Drug Profile
Research programme: pain therapeutics - AstraZeneca
Alternative Names: AZ 09; AZ 11760788; AZ 12048189; AZ 12099548; AZ 1297442; AZ 599; AZD 7903; AZD 9335Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class 3-ring heterocyclic compounds; Indoles; Isoxazoles; Pyridines; Sulfonamides
- Mechanism of Action Bradykinin B2 receptor antagonists; Cannabinoid receptor CB1 agonists; Nav1.7 voltage-gated sodium channel inhibitors; Sodium channel antagonists; TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory pain; Neuropathic pain
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-pain in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (IV, Infusion)
- 31 Aug 2012 Pharmacodynamics data from a Preclinical trial in Neuropathic pain presented at the 14th World Congress on Pain (WCP-2012)